A multicenter randomized, controlled feasibility and pilot study completed in 2014 concludes that full clinical trial of spinal cord stimulation (SCS) as a therapeutic alternative for refractory chronic angina pectoris is warranted. Chronic angina pectoris patients experience severe pain upon even mild exertion as a consequence of their nerve endings having become hypersensitized due to restricted blood flow (ischemia). The condition leads to frequent hospitalization and poor health related quality of life. The results of the pilot study, funded in 2010 by the National Institute for Health Research, were presented earlier this week at the 12th World Congress of the International Neuromodulation Society.
Senior author Sam Eldabe, MD, of James Cook University Hospital in Middlesbrough, UK, commented “There is a need for large, high-quality research studies to clarify the role of spinal cord stimulation in the treatment continuum for chronic angina pectoris, which may not respond sufficiently to pharmaceuticals and for which revascularization procedures may not be feasible or the risk unjustified.” SCS has been used in refractory chronic angina pectoris in Europe since the 1980s, but acceptance by cardiologists has been low. In this pilot study of 29 patients, all completed the study, showing that study burden was feasible, and there were no device-related serious adverse events over the 6-month follow-up period.
To read about SCS and diabetes, click here.
To read about spinal cord stimulation implants, click here.
For a link to a video in which Dr. Bruce Nicholson discusses spinal cord stimulation, click here.
To read more about high-frequency SCS, click here.
Read a news story about the conclusions here.